Cubist Pharmaceuticals' development of Cubicin, an antibiotic for methicillin-resistant Staphylococcus aureus bacteria, has led to a dramatic increase in revenue and the biotech firm's transformation into one of Massachusetts' best-performing companies. Cubicin's success has enabled Cubist to broaden its pipeline through drug development and marketing deals with companies such as Dyax Corp., which is currently working on a treatment to prevent blood loss during surgery.

Related Summaries